Literature DB >> 10792333

Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients.

S Kasayama1, M Otsuki, M Takagi, H Saito, S Sumitani, H Kouhara, M Koga, Y Saitoh, T Ohnishi, N Arita.   

Abstract

OBJECTIVE: Abnormal glucose tolerance is often demonstrated in acromegalic patients. Although insulin resistance is a common feature of acromegaly, it remains unclear whether the extent of insulin resistance per se determines the abnormal glucose tolerance. In order to elucidate this issue, we investigated insulin sensitivity and beta-cell function in acromegalic patients.
DESIGN: Twenty-four acromegalic patients were studied in comparison with 24 healthy control subjects. To estimate insulin sensitivity and beta-cell function, we used correct homeostasis model assessment (HOMA) model, a computer-solved model. We also investigated the effects of surgical success on both parameters.
RESULTS: HOMA insulin sensitivity (HOMA-%S) in the acromegalic patients was 74 +/- 51 (SD)%, significantly lower than that in 24 healthy controls (144 +/- 49%). HOMA-%S in 12 normal glucose tolerance (NGT) patients was 54 +/- 31%, not significantly different from that in impaired glucose tolerance (IGT; n = 11) or diabetes mellitus (DM; n = 1) patients (93 +/- 60%). By contrast, HOMA beta-cell function (HOMA-%beta) in the NGT acromegalic patients was 163 +/- 67%, significantly higher than the IGT/DM acromegalic patients (89 +/- 34%) and the healthy controls (72 +/- 19%). In 11 patients who achieved complete normalization of GH excess after surgery, HOMA-%S significantly increased to control ranges (from 76 +/- 26 to 159 +/- 61%) within 2 weeks after the surgical success.
CONCLUSIONS: We conclude that insulin sensitivity is reduced to a similar extent in acromegalic patients with normal glucose tolerance and those with impaired glucose tolerance or diabetes. Compensatory hyperfunction of beta-cells appears to counterbalance the reduced insulin sensitivity in the acromegalic patients with normal glucose tolerance but not in those with impaired glucose tolerance or diabetes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792333     DOI: 10.1046/j.1365-2265.2000.00986.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  41 in total

Review 1.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

Review 2.  Acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

Review 3.  Diabetes in Patients With Acromegaly.

Authors:  A M Hannon; C J Thompson; M Sherlock
Journal:  Curr Diab Rep       Date:  2017-02       Impact factor: 4.810

4.  Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.

Authors:  R Helseth; S M Carlsen; J Bollerslev; J Svartberg; M Øksnes; S Skeie; S L Fougner
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

5.  Evaluation of macular and peripapillary choroidal thickness, macular volume and retinal nerve fiber layer in acromegaly patients.

Authors:  Serpil Yazgan; Dilek Arpaci; Haci Ugur Celik; Irem Isik
Journal:  Int Ophthalmol       Date:  2017-05-15       Impact factor: 2.031

6.  Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients.

Authors:  Orsalia Alexopoulou; Marie Bex; Peter Kamenicky; Augustine Bessomo Mvoula; Philippe Chanson; Dominique Maiter
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

7.  Effects of two different somatostatin analogs on glucose tolerance in acromegaly.

Authors:  C Ronchi; P Epaminonda; V Cappiello; P Beck-Peccoz; M Arosio
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

Review 8.  Medical consequences of acromegaly: what are the effects of biochemical control?

Authors:  Annamaria Colao; Renata S Auriemma; Rosario Pivonello; Mariano Galdiero; Gaetano Lombardi
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

9.  Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.

Authors:  Laura De Marinis; Antonio Bianchi; Alessandra Fusco; Vincenzo Cimino; Marilda Mormando; Laura Tilaro; Gherardo Mazziotti; Alfredo Pontecorvi; Andrea Giustina
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.